Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer's disease: A randomized, double-blind, and placebo-controlled study

被引:32
|
作者
Akhgarjand, Camellia [1 ]
Vahabi, Zahra [2 ,3 ]
Shab-Bidar, Sakineh [4 ]
Etesam, Farnaz [5 ]
Djafarian, Kurosh [1 ]
机构
[1] Univ Tehran Med Sci, Sch Nutr Sci & Dietet, Dept Clin Nutr, Tehran, Iran
[2] Univ Tehran Med Sci, Roozbeh Hosp, Dept Psychiat, Cognit Neurol & Neuropsychiat Div, Tehran, Iran
[3] Univ Tehran Med Sci, Ziaeeian Hosp, Dept Geriatr, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Nutr Sci & Dietet, Dept Community Nutr, Tehran, Iran
[5] Univ Tehran Med Sci, Sina MS Res Ctr, Brain & Spinal Injury Res Ctr, Tehran, Iran
来源
FRONTIERS IN AGING NEUROSCIENCE | 2022年 / 14卷
关键词
Alzheimer's disease; cognition; psychological test; probiotic; oral supplementation; MINI-MENTAL-STATE; INSTRUMENTAL ACTIVITIES; PERFORMANCE; LACTOBACILLI; POPULATION; DIAGNOSIS; DEMENTIA; MEMORY;
D O I
10.3389/fnagi.2022.1032494
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Probiotics have been suggested as an effective adjuvant treatment for Alzheimer's disease (AD) due to their modulating effect on the gut microbiota, which may affect the gut-brain axis. Therefore, we aimed to evaluate the effects of two different single-strain probiotics on cognition, physical activity, and anxiety in subjects with mild and moderate AD. Eligible patients (n = 90) with AD were randomly assigned to either of two interventions [Lactobacillus rhamnosus HA-114 (10(15) CFU) or Bifidobacterium longum R0175 (10(15) CFU)] or placebo group, receiving probiotic supplement twice daily for 12 weeks. The primary outcome of the study was cognitive function measured by using the two tests, namely, the Mini-Mental State Examination (MMSE) and the categorical verbal fluency test (CFT). Secondary outcomes included a performance in Activities of Daily Living (ADL), the Lawton Instrumental Activities of Daily Living (IADL) scale, and the Generalized Anxiety Disorder (GAD-7) scale. Linear mixed-effect models were used to investigate the independent effects of probiotics on clinical outcomes. After 12 weeks, MMSE significantly improved cognition (P-Interaction < 0.0001), with post hoc comparisons identifying significantly more improvement in the B. longum intervention group (differences: 4.86, 95% CI: 3.91-5.81; P < 0.0001) compared with both the placebo and L. rhamnosus intervention groups (differences: 4.06, 95% CI: 3.11-5.01; P < 0.0001). There was no significant difference between the two intervention groups (differences: -0.8, 95% CI: -1.74 to 0.14; P = 0.09). In conclusion, this trial demonstrated that 12-week probiotic supplementation compared with placebo had beneficial effects on the cognition status of patients with AD.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] A Phase III, Placebo-Controlled, Double-Blind, Randomized Trial of Tramiprosate in the Clinical Management of Patients with Mild-to-Moderate Alzheimer's Disease (the Alphase Study)
    Aisen, Paul
    Gauthier, Serge
    Ferris, Steven
    Garceau, Denis
    Saumier, Daniel
    Duong, Anh
    Sampalis, John
    NEUROLOGY, 2009, 72 (11) : A271 - A271
  • [32] Effects of a probiotic fermented milk on functional constipation: A randomized, double-blind, placebo-controlled study
    Mazlyn, Mena Mustapha
    Nagarajah, Lee Hun-Leong
    Fatimah, Arshad
    Norimah, A. Karim
    Goh, Khean-Lee
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (07) : 1141 - 1147
  • [33] A double-blind, randomized investigation of the effects of testosterone or placebo in male patients with mild-to-moderate Alzheimer's disease
    Miller, B
    DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE, 2000, 2002, : 253 - 262
  • [34] Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled study
    Alberda, C
    Gramlich, L
    Field, C
    McCargar, L
    Meddings, J
    Madsen, K
    GASTROENTEROLOGY, 2005, 128 (04) : A281 - A282
  • [35] Effects of Probiotic Use on Quality of Life and Physical Activity in Constipated Female University Students: A Randomized, Double-Blind Placebo-Controlled Study
    Kommers, Michelle Jalousie
    Silva Rodrigues, Rosilene Andrade
    Miyajima, Fabio
    Zavala Zavala, Arturo Alejandro
    Leite Moreno Ultramari, Viviane Regina
    Rezende Fett, Waleria Christiane
    Balogun, Sikiru Olaitan
    de Oliveira, Ruberlei Godinho
    Fett, Carlos Alexandre
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2019, 25 (12) : 1163 - 1171
  • [36] A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine
    Hu, Yuan
    Wang, Yichen
    Chen, Chao
    Yang, Wenshan
    Zhu, Weiyu
    Wang, Yuanbo
    Liu, Ping
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 281
  • [37] Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomized and placebo-controlled trial
    Akhondzadeh, S
    Noroozian, M
    Mohammadi, M
    Ohadinia, S
    Jamshidi, AH
    Khani, M
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (01) : 53 - 59
  • [38] Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study
    Henderson, Samuel T.
    Poirier, Judes
    BMC MEDICAL GENETICS, 2011, 12
  • [39] Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study
    Schrader, E
    Meier, B
    Brattstrom, A
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1998, 13 (03) : 163 - 169
  • [40] A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
    Sano, M.
    Bell, K. L.
    Galasko, D.
    Galvin, J. E.
    Thomas, R. G.
    van Dyck, C. H.
    Aisen, P. S.
    NEUROLOGY, 2011, 77 (06) : 556 - 563